Nuron Chooses Merck BioManufacturing for MS Drug

Nuron Biotech selected the Merck BioManufacturing Network to produce large-scale GMP supplies of NU10.

Nuron Biotech, Inc. has chosen the Merck BioManufacturing Network to produce large-scale GMP clinical supplies of NU100 and to provide process validation leading to long-term commercial operations. NU100 is a recombinant human interferon beta compound being developed for the treatment of multiple sclerosis.

"The novel steps in manufacturing that make NU100 unique are important to the success of our product development program,” said Shankar Musunuri, Ph.D., MBA, chief executive officer and founder of Nuron Biotech. “The experience and breadth of capabilities offered by Merck BioManufacturing Network match our needs in both the clinical trial production as well as commercialization of our unique product for patients with MS.”

Steve Bagshaw, site ge